Clinical Trials Sponsored by Southeastern Gynecologic Oncology

Total 304 results

Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Trial for Patients With Advanced/Recurrent Cervical Cancer

Cervical Intraepithelial Neoplasia | Uterine Neoplasms | Genital Neoplasms, Female

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
Gynecologic Oncology Associates
Merck Sharp & Dohme LLC

Completed

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Ovarian Cancer | Uterine Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada, United Kingdom, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Cancer

United States
M.D. Anderson Cancer Center
Gynecologic Oncology Group

Completed

Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171

Cervical Cancer | Precancerous Condition
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer

Cervical Cancer
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Trial for Patients With Gestational Trophoblastic Disease

Uterine Neoplasms | Trophoblastic Neoplasms | Hydatidiform Mole | Choriocarcinoma

United States
Far Eastern Memorial Hospital
Gynecologic Oncology Group

Recruiting

Ketohexokinase Isoforms in Endometrial Cancer.

Endometrial Cancer

Taiwan
Far Eastern Memorial Hospital
Gynecologic Oncology Group

Recruiting

The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer

Vulvar Cancer, G9a Protein

Taiwan
Eli Lilly and Company
Gynecologic Oncology Group

Completed

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

Neoplasms | Carcinoma | Ovarian Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Recurrent Uterine Sarcoma | Uterine Leiomyosarcoma

United States
Far Eastern Memorial Hospital
Gynecologic Oncology Group

Completed

Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer

Cervical Cancer

Taiwan
Asan Medical Center
Korean Gynecologic Oncology Group

Unknown

Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer

Endometrial Cancer

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

Cervical Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Cervical Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada, United Kingdom, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer

Endometrial Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium | Neoplasms, Endometrial

United States
AbbVie
Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology...

Terminated

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

Ovarian Cancer | Ovarian Neoplasm

United States, Australia, Brazil, Denmark, Israel, Japan, Korea, Republic of, New Zealand, Poland, Spain, United Kingdom
Radiation Therapy Oncology Group
National Cancer Institute (NCI); Gynecologic Oncology Group

Completed

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Endometrial Cancer

United States, Norway
The Central and Eastern European Gynecologic Oncology...

Recruiting

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy (CERVANTES)

Cervical Cancer

Czechia
CanariaBio Inc.
Gynecologic Oncology Group; Iqvia Pty Ltd

Active, not recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Peritoneal Carcinoma | Peritoneal Cancer | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma

Korea, Republic of, United States, Taiwan, Czechia, Argentina, Spain, Belgium, Brazil, Chile, Canada, Italy, Hungary, India, Mexico
National Cancer Center, Korea
Korean Gynecologic Oncology Group

Completed

Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer (PALME)

Endometrial Cancer

Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI); Southwest Oncology Group

Completed

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

Ovarian Cancer

United States, Japan
Karyopharm Therapeutics Inc
Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German... and other collaborators

Active, not recruiting

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (ENGOT-EN5)

Endometrial Cancer

United States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Samples From Patients With Endometrial Cancer

Lynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection (GROINSS-V)

Stage III Vulvar Cancer | Vulvar Squamous Cell Carcinoma | Stage I Vulvar Cancer | Stage II Vulvar Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Ovarian Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7

Clinical Trials Sponsored by Southeastern Gynecologic Oncology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations